The
As a medical treatment for acromegaly, bromocriptine has been widely used (Daughaday, 1985 ; Frohman, 1987) .
With this treatement, however, normalization of plasma GH is obtained in only about 20% of cases (Faglia et al., 1985) . We have already reported that dopaminergic agents, which can cross the blood brain barrier, might have a dual action on GH secretion in acromegalic patients ; one is a direct somatotroph inhibition and another is a indirect somatotroph stimulation via the CNS (Hanew et al., 1987) . Therefore, it seems likely that bromocriptine therapy is not effective in acromegalic patients whose hypothalamic GHRH secretions are stimulated by bromocriptine.
In such cases, the combination of hypothalamic GH suppressants with bromocriptine might be desirable (Hanew et al., 1987 bromocriptine therapy, and fell again after the recommencement of cyproheptadine administration (Fig. 2) . Plasma GH levels in one patient (# 8) remained in the low normal ranges and the response to TRH disappeared (data not shown) even after the cessation of both agents, and this patient was considered to be cured completely (Fig.2) . Table 2 . Plasma Sm-C values (U/ml) before and during the bromocriptine (BC) and cyproheptadine (Cypro) therapy in 8 GH normalized patients with combination therapy L, P < 0.05) (Fig. 3a) .
Plasma GH response to GHRH was also slightly suppressed by the single bromocriptine therapy compared to the pretreatment response (P = NS). The response was markedly suppressed by the addition of cyproheptadine (pretreatment vs combined treat-3) Pituitary adenoma size before and during the bromocriptine and cyproheptadine therapy in previously untreated acromegalic patients. Seven acromegalic patients, who were previously untreated, received a pituitary CT-scan before treatment and during the bromocriptine and cyproheptadine treatment. The CT-scan during the combination therapy was performed 8 to 44 months after the start of the therapy.
Four of seven patients showed a reduction in the tumor size (maximal height) exceeding the a b Fig.3 .
Plasma GH responses to TRH (a) and GHRH (b) in 6 acromegalic patients before and during the single bromocriptine (BC) or the combined bromocriptine and cyproheptadine treatment (BC+Cypro).
vs pretreatment: *1, P<0.05; *2, P<0.02; *3, P <0.01; *4, P< 0.005 Endocrinol. Japon. CT slice width (1.5-3mm) (Table 3) . CT changes in most representative cases (# 11, 13) are shown in Fig. 4 . 
Discussion
In this study, eight out of 15 acromegalic patients, in whom GH normalization was not achieved with bromocriptine therapy alone, showed GH normalization after the combination therapy with bromocriptine and cyproheptadine.
Plasma GH responses to TRH or GHRH were also significantly inhibited in these patients, and a clear reduction in the tumor size was observed in 4 of 7 patients, whereas consistent results have not yet been obtained regarding the effect of single bromocriptine therapy on tumor size in acromegalic patients (Faglia et al., 1985, Besser and Wass, 1987) .
Although bromocriptine is known to inhibit GH secretion in acromegalic patients by its direct action on the pituitary adenoma (Molinatti et al., 1984) , the possibility of simultaneous GH stimulation via the hypothalamus has been proposed by us (Hanew et al., 1987) and Camanni et al. (1977) . Cyproheptadine is reported to inhibit sleep-induced GH secretion and GH responses to several exogenous stimuli, which probably mediate the stimulation of hypothalamic GHRH or the inhibition of hypothalamic somatostatin release in normal subjects (Bivens et al., 1973; Nakai et al., 1975; Smyth et al., 1974; Nakai et al., 1975; Chihara et al., 1976; Dammacco et al., 1977; Hainer et al., 1981; Alba-Roth et al., 1988) . Cyproheptadine has antiserotonergic, anti-histaminergic and weak anti-cholinergic actions (Williams and Martin, 1982) . The GH inhibitory action of the cyproheptadine might be due to the antiserotonergic action, since 5HTP (5-hydroxytryptophan : the precursor of serotonin)-induced GH release is inhibited by pretreatment with cyproheptadine (Nakai et al., 1974) , This action might take place at the level of the hypothalamus. However, because plasma GH response to TRH and GHRH was significantly blunted and pituitary tumor size was clearly reduced in 4 of 7 patients during the bromocriptine and cyproheptadine combination therapy, cyproheptadine might have a direct suppressive effect on pituitary adenomas.
Concerning this, Ishibashi et al., (1985) have reported that cyproheptadine inhibited GH secretion from GH secreting tumors in vitro, probably through a non-serotonergic mechanism.
In addition to such direct suppressive effects, we should consider the possibility that functional and morphological changes were caused by a chronic suppression of GHRH and/or chronic stimulation of somatostatin secretion from the hypothalamus.
Previous animal experiments revealed no direct effect of serotonin on basal GH secretion (Kato et al., 1980; Hail, 1982; Hall et al., 1984) . With a histochemical technique, synaptic connections between serotonergic nerve endings and somatostatin neurons have been observed in the rat anterior periventricular nucleus (Kiss et al., 1988) . Alhough serotonin has been reported to have an inhibitory (Richardson et al., 1981) or no effect (Chihara et al., 1979; Peterfreund and Vale 1983) 
